Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Resiquimod Pegol · NKTR-262

Small molecule · Immune activation, directed at Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) · developed by Nektar Therapeutics

Phase 1/2 Most advanced trial (none active)
NKTR Developer
1 Registered trials

What is Resiquimod Pegol?

Resiquimod pegol is a TLR7/8 agonist attached to polyethylene glycol through a hydrolyzable glycine linker, given intratumorally. It binds and activates TLR7 and TLR8 on antigen-presenting cells such as dendritic cells, promoting immune responses against tumor-associated antigens. It is being studied in melanoma, Merkel cell carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, renal cell carcinoma, colorectal cancer, and sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NKTR-262
Drug type
Small molecule
Targets
Toll-like receptor 7 (TLR7), Toll-like receptor 8 (TLR8)
Mechanism
Immune activation, directed at Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8)
Pathways
TLR7/8-mediated innate immune signaling, dendritic cell maturation and activation, pro-inflammatory cytokine production, cytotoxic T-lymphocyte and B-lymphocyte responses
Therapy area
Oncology
Developer
Nektar Therapeutics (NKTR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
OYZ8U57WZU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03435640 Phase 1/2 Melanoma Terminated NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerHead and Neck Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaRenal Cell CarcinomaSarcomaTriple Negative Breast Cancer

Other drugs acting on TLR7 / TLR8

More from Nektar Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.

Follow NKTR, the company behind Resiquimod Pegol

See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.